(SPA, BLRX, SURW) CRWENewswire Stocks In Action
BioLineRx Ltd BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C. According to a definitive agreement between the companies, Consolidated Communications Holdings will acquire all the outstanding shares of SureWest Communications - SURW - in a cash and stock transaction valued at $23.00 per share, or a total of approximately $340.9 million, exclusive of debt. Sparton Corp - SPA - reported that it has been awarded an approximately $7.6 million contract by Australia to manufacture the AN/SSQ-62E and AN/SSQ-53F sonobuoys.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

ユーザー：karmastock
再生時間：00:01:21
投稿日時：12/02/07 4:46
カテゴリ：ビジネス全般 
タグ： SPA  Sparton  BLRX  SURW  Nasdaq:BLRX  NYSE:SPA  Nasdaq:SURW 

[ 前ページへ戻る ]